Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
BMS-986301 acts as an agonist of Stimulator of interferon genes (STING1), which potentially results in improved antitumor immune response (PMID: 30400822).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|BMS-986301||BMS986301|BMS 986301||STING1 Agonist 17||BMS-986301 acts as an agonist of Stimulator of interferon genes (STING1), which potentially results in improved antitumor immune response (PMID: 30400822).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03956680||Phase I||Ipilimumab + Nivolumab BMS-986301||An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers||Active, not recruiting||USA | CAN||0|